Avenir Wellness Solutions, Inc.

OTCPK:AVRW Stock Report

Market Cap: US$2.4m

Avenir Wellness Solutions Valuation

Is AVRW undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AVRW when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate AVRW's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate AVRW's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for AVRW?

Key metric: As AVRW is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for AVRW. This is calculated by dividing AVRW's market cap by their current revenue.
What is AVRW's PS Ratio?
PS Ratio1.2x
SalesUS$2.05m
Market CapUS$2.36m

Price to Sales Ratio vs Peers

How does AVRW's PS Ratio compare to its peers?

The above table shows the PS ratio for AVRW vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average10.4x
TSOI Therapeutic Solutions International
36xn/aUS$3.6m
CPHI China Pharma Holdings
0.7xn/aUS$3.7m
CANB Can B
4xn/aUS$3.8m
PTPI Petros Pharmaceuticals
0.7x39.8%US$2.7m
AVRW Avenir Wellness Solutions
1.2xn/aUS$2.4m

Price-To-Sales vs Peers: AVRW is good value based on its Price-To-Sales Ratio (1.2x) compared to the peer average (10.4x).


Price to Sales Ratio vs Industry

How does AVRW's PS Ratio compare vs other companies in the US Pharmaceuticals Industry?

72 CompaniesPrice / SalesEstimated GrowthMarket Cap
OGN Organon
0.6x-0.06%US$3.94b
PRGO Perrigo
0.9x3.4%US$3.83b
BHC Bausch Health Companies
0.3x1.5%US$2.93b
AMRX Amneal Pharmaceuticals
1x5.6%US$2.60b
AVRW 1.2xIndustry Avg. 2.8xNo. of Companies72PS048121620+
72 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: AVRW is good value based on its Price-To-Sales Ratio (1.2x) compared to the US Pharmaceuticals industry average (2.8x).


Price to Sales Ratio vs Fair Ratio

What is AVRW's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AVRW PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.2x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate AVRW's Price-To-Sales Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies